RecruitingPhase 2NCT06452706

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

The Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection in Human Epidermal Growth Factor Receptor 2 (HER2) Negative Recurrent/Metastatic Breast Cancer

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Enrollment

42 participants

Start Date

Nov 14, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called TQB2102 in patients with HER2-negative breast cancer that has come back or spread to other organs. HER2-negative means the tumor lacks a protein called HER2 that some other breast cancer drugs target, so new options are needed for this group. **You may be eligible if...** - You are aged 18–75 with HER2-negative breast cancer that has returned or spread and cannot be treated with surgery or radiation - Your cancer has progressed after at least one standard chemotherapy regimen (and if hormone receptor-positive, after CDK4/6 inhibitor therapy) - You have at least one measurable tumor on imaging - You are in good health (ECOG score 0 or 1) with an expected survival of over 3 months **You may NOT be eligible if...** - Your cancer is HER2-positive - You have not tried prior standard systemic treatments - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTQB2102 for injection

TQB2102 for injection is a HER2 dual-antibody-drug conjugate (ADC).

Locations(16)

Bozhou People's Hospital

Bozhou, Anhui, China

Chuzhou First People's Hospital

Chuzhou, Anhui, China

Anhui Provincial Public Health Clinical Center

Hefei, Anhui, China

Ma'anshan People's Hospital

Ma’anshan, Anhui, China

Wuhu Hospital Affiliated to East China Normal University

Wuhu, Anhui, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

The Third People's Hospital of Zhengzhou

Zhengzhou, Henan, China

The First People's Hospital of Zhengzhou

Zhengzhou, Henan, China

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

The First People's Hospital of Changde City

Changde, Hunan, China

Ruijin Hospital ,Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China

Cancer Hospital Affiliated to Xinjiang Medical University

Ürümqi, Xinjiang, China

Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, China

Suzhou Municipal Hospital

Suzhou, Zhejiang, China

Wenzhou Medical University Affiliated First Hospital

Wenzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06452706

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

NCT062589931 location

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828764 locations

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

NCT061297472 locations

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521158 locations